Avis Budget Group is a provider of mobility solutions through its three brands, Avis, Budget and Zipcar, together with several other brands. The company has two segments: Americas, which provides and licenses the company's brands to third parties for vehicle rentals and ancillary products and services in North America, South America, Central America and the Caribbean, and operates its car sharing business in certain of these markets; and International, which provides and licenses the company's brands to third parties for vehicle rentals and ancillary products and services in Europe, the Middle East, Africa, Asia and Australasia, and operates the company's car sharing business in certain of these markets.

Conduent is a holding company. Through its subsidiaries, the company is a provider of business process services in transaction-intensive processing, analytics and automation. The company's Commercial Industries segment provides business process services and customized solutions to clients in a variety of industries. The company's Government Services segment provides government-centric business process services to U.S. federal, state and local and foreign governments for transportation, public assistance, program administration, transaction processing and payment services. The company's Transportation segment provides systems and support services to transportation departments and agencies globally.

GTY is a holding company. Through its subsidiaries, the company is a public sector Software as a Service company which provides a cloud-based suite of solutions. The company's segments: Bonfire Interactive Ltd.,which provides SaaS application; CityBase, Inc., which provides content, digital services, and integrated payments; eCivis Inc., which provides grants management and indirect cost reimbursement solutions; Open Counter Enterprises Inc., which develops and provides software tools; and Questica Inc. and Questica USCDN Inc., which designs and develops capital and operating budgeting software; and Sherpa Government Solutions LLC, which provides of public sector budgeting software and consulting services.

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. The company has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.